Contribute Try STAT+ Today

The World Health Organization added a Regeneron Pharmaceuticals medication to its list of recommended treatments for Covid-19, and at the same time, joined Unitaid in criticizing the company’s pricing and distribution of the drug globally.

As part of their message, the agencies also urged Regeneron to transfer technology used to make its monoclonal antibody to other manufacturers so that lower-cost biosimilar versions could be made more quickly for low and middle-income nations. They also directed the message at Roche (RHHBY), which struck a deal with Regeneron to make the treatment for distribution outside the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment